Fuxiang Pharmaceutical (300497.SZ): Signed the “Termination Agreement on Shareholders' Special Rights”
Gelonghui, May 30丨Fuxiang Pharmaceutical (300497.SZ) announced that currently, since Ling Kai Pharmaceutical is planning an initial public offering and listing plan on the Hong Kong Stock Exchange Limited, in order to comply with the regulations and requirements of laws and regulations, the Hong Kong Stock Exchange, the Hong Kong Securities and Futures Commission, the China Securities Regulatory Commission, etc., the parties agreed to terminate the performance compensation, repurchase rights, and shareholder special “Shareholders' Agreement” on the day before the date Ling Kai Pharmaceutical first submitted the listing application form to the Hong Kong Stock Exchange Before signing the “Termination of Rights Agreement”
Fuxiang Pharmaceutical (300497.SZ): “Artificial meat” is one of the main application areas of microbial proteins that the company has mass-produced
Gelonghui, May 11 | Fuxiang Pharmaceutical (300497.SZ) said on the investor interactive platform that “artificial meat” is one of the main application areas of microbial proteins that the company has mass-produced. In addition, the company's microbial protein can also be widely used in protein drinks, health foods, specialty foods, pet food, etc., and has characteristics such as high protein, high dietary fiber, low sugar, low fat, zero cholesterol, zero trans fatty acids, etc., and has been tested to contain 18 kinds of amino acids needed by the human body.
Fuxiang Pharmaceutical (300497.SZ): Currently building its own multi-functional synthetic bio-biological fermentation production line
Gelonghui, May 9 | Fuxiang Pharmaceutical (300497.SZ) said on the investor interactive platform that synthetic biology is an emerging discipline that uses renewable biomass as raw materials and organisms as production media to transform or create artificial life systems. Synthetic biology has characteristics such as being clean, efficient, and renewable. It has the potential to completely disrupt the current pattern at both the level of technology and industrial innovation, and is an important development direction for the company. Currently, the company has built its own multi-functional synthetic bio-biological fermentation production line, and has accumulated deep experience in biological fermentation technology, which is mainly used in the fields of medicine and food. The company's various enzyme preparations, hydroxyproline
Fuxiang Pharmaceutical (300497.SZ): Actual controller Bao Jianhua completed an increase of 2.351,000 shares
Gelonghui, May 7 | Fuxiang Pharmaceutical (300497.SZ) announced that as of the announcement date, Mr. Bao Jianhua, the controlling shareholder, actual controller and chairman of the company, had increased his holdings by 2.351,000 shares through centralized bidding, to an increase of 25.134,400 yuan. His current holdings increase plan has been completed.
There's Reason For Concern Over Jiangxi Fushine Pharmaceutical Co., Ltd.'s (SZSE:300497) Massive 26% Price Jump
Despite an already strong run, Jiangxi Fushine Pharmaceutical Co., Ltd. (SZSE:300497) shares have been powering on, with a gain of 26% in the last thirty days. But the gains over the last month wer
Jiangxi Fushine Pharmaceutical (SZSE:300497) Is Carrying A Fair Bit Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Fuxiang Pharmaceutical (300497.SZ): Net profit of 1.468,500 yuan for the first quarter reversed the year-on-year loss
Gelonghui, April 28 | Fuxiang Pharmaceutical (300497.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 340 million yuan, a year-on-year decrease of 14.45%; net profit attributable to shareholders of listed companies was 1.468,500 yuan, which turned a year-on-year loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 10.21 million yuan; basic earnings per share.
SDIC Securities: The logic of each segment of biomaneling is different, and there is a possibility that many tracks will break the game
According to the 2023 “Global and Chinese Plant Extract Industry Analysis Report”, the total scale of the global plant extraction industry will reach 30 billion US dollars in 2021, and the Chinese market is expected to reach 80 billion yuan in 2028. In the future, bio-manufacturing will replace plant extraction to reduce costs and increase efficiency, which is expected to open up the downstream market.
Subdued Growth No Barrier To Jiangxi Fushine Pharmaceutical Co., Ltd. (SZSE:300497) With Shares Advancing 29%
Jiangxi Fushine Pharmaceutical Co., Ltd. (SZSE:300497) shares have had a really impressive month, gaining 29% after a shaky period beforehand. Unfortunately, the gains of the last month did little
Fuxiang Pharmaceutical (300497.SZ): The park where the subsidiary is located has passed the Jiangxi Chemical Industry Park certification
Gelonghui, Feb. 29丨Fuxiang Pharmaceutical (300497.SZ) announced. Recently, the Jiangxi Provincial Department of Industry and Information Technology issued the “Notice on Announcing the Certification Results of Yushan Pharmaceutical Industrial Park in Jingdezhen Ceramics Industrial Park”. According to the requirements of the “Jiangxi Chemical Park Construction Standards and Accreditation Administration Implementation Rules (Trial)”, according to the work procedures stipulated in the “Jiangxi Chemical Park Accreditation Work Process (Trial)” and “Notice on Simplifying the Jiangxi Chemical Park Accreditation Work Process”, Yushan Pharmaceutical Industrial Park in Jingdezhen Ceramics Industrial Park passed the certification with the approval of the Jiangxi Provincial People's Government.
Fuxiang Pharmaceutical (300497.SZ): Li Huiyue increased her holdings by a total of 100,000 shares
Gelonghui, Feb. 28 | Fuxiang Pharmaceutical (300497.SZ) announced that as of the date of this announcement, Mr. Li Huiyue had increased his holdings by 100,000 shares through centralized bidding, to an increase of 915,000 yuan. His current plan to increase his holdings has been completed.
Fuxiang Pharmaceutical (300497.SZ): Deputy General Manager Dai Zhenliang completed an increase of 80,000 shares
Gelonghui, Feb. 21丨Fuxiang Pharmaceutical (300497.SZ) announced that recently, the company received a notice from Mr. Dai Zhenliang, the deputy general manager, that the increase in the company's shares has been completed. As of the announcement date, Mr. Dai Zhenliang increased his holdings of the company by 80,000 shares through centralized bidding, to an increase of 592,600 yuan. The plan to increase his holdings has already been completed.
Fuxiang Pharmaceutical (300497.SZ): Financial Director Yang Guang completed an increase of 47,600 shares
Gelonghui, Feb. 20 | Fuxiang Pharmaceutical (300497.SZ) announced that recently, the company received a notice from the financial director, Mr. Yang Guang, that it has completed the implementation of increasing its shareholding in the company. As of the date of this announcement, Mr. Yang Guang increased his holdings of the company by 47,600 shares through centralized bidding, to an increase of 301,940 yuan. The plan to increase his holdings has already been completed.
Fuxiang Pharmaceutical (300497.SZ): Xiangtai Scientific obtained a notice of approval for the marketing application of chemical raw materials
Gelonghui, Feb. 18, 丨 Fuxiang Pharmaceutical (300497.SZ) announced that recently, Jiangxi Xiangtai Life Science Co., Ltd. (“Xiangtai Science”), a wholly-owned subsidiary of Jiangxi Fuxiang Pharmaceutical Co., Ltd., received the approval and issuance of the “Notice of Approval of the Marketing Application for Chemical Ingredients” for tazobactam sodium raw materials from the State Drug Administration. Tazobactam sodium is an irreversible competitive beta-lactamase inhibitor. It is a third-generation antimicrobial potentiator. It can inhibit the activity of beta-lactamase, make the enzyme activity irreversible, prevent the sensitivity of antibiotics from decreasing, and also avoid developing drug resistance and increasing antibiotics as much as possible
Fuxiang Pharmaceutical (300497.SZ): Controlling shareholders pledge an additional 4.5 million shares
Gelonghui, Feb. 8 | Fuxiang Pharmaceutical (300497.SZ) announced that the company recently received a notice from Mr. Bao Jianhua, the controlling shareholder and actual controller, about additional pledges for some of the company's shares. The total number of pledges this time is 4.5 million shares.
Fuxiang Pharmaceutical (300497.SZ): Deputy General Manager Chen Yinghui completed an increase of 82,000 shares
Gelonghui, Feb. 5 | Fuxiang Pharmaceutical (300497.SZ) announced that recently, the company received a notice from Deputy General Manager Mr. Chen Yinghui that the increase in the company's shares had been completed. As of the date of this announcement, Mr. Chen Yinghui had increased his holdings by 82,000 shares through centralized bidding, increasing his holdings by RMB 504,366. The implementation of his current holdings increase plan has been completed.
Fuxiang Pharmaceutical (300497.SZ): Controlling shareholders, chairman and vice chairman, and some executives plan to increase the company's shares by a total of 27.6 million yuan to 55.2 million yuan
Gelonghui, Feb. 1, Fuxiang Pharmaceutical (300497.SZ) announced that the controlling shareholder, actual controller and chairman of the company, Mr. Li Huiyue, Vice Chairman, Mr. Liu Ying, Mr. Zhang Xiangming, Mr. Dai Zhenliang, Mr. Wei Haipeng, Mr. Chen Yinghui, Financial Director Mr. Yang Guang, and Ms. Peng Yun, Deputy General Manager and Board Secretary, intend to increase the company's stock holdings through centralized bidding or other methods permitted by laws and regulations; the total increase amount is not less than RMB 27.6 million and no more than RMB 55.2 million (all inclusive); The implementation period of the holding plan is at its own cost 6 months from the date of disclosure of the announcement
The controlling shareholder of Fuxiang Pharmaceutical (300497.SZ) lifted the pledge of 11.96 million shares
Fuxiang Pharmaceutical (300497.SZ) issued an announcement. The company recently received a package from the controlling shareholder, actual controller and chairman...
The Market Doesn't Like What It Sees From Jiangxi Fushine Pharmaceutical Co., Ltd.'s (SZSE:300497) Revenues Yet
You may think that with a price-to-sales (or "P/S") ratio of 2.3x Jiangxi Fushine Pharmaceutical Co., Ltd. (SZSE:300497) is a stock worth checking out, seeing as almost half of all the Pharmaceuticals
Fuxiang Pharmaceutical (300497.SZ) and Ruyi Technology once again passed the high-tech enterprise certification
Gelonghui, January 31 | Fuxiang Pharmaceutical (300497.SZ) announced that the company and its wholly-owned subsidiary Jiangxi Ruyi Technology Development Co., Ltd. (“Ruyi Technology”) recently received the “High-tech Enterprise Certificate” jointly issued by the Jiangxi Provincial Department of Science and Technology, the Jiangxi Provincial Department of Finance, and the Jiangxi Provincial Taxation Bureau of the State Administration of Taxation. The company and Ruyi Technology were once again recognized as high-tech enterprises. The certificate numbers are: GR202336000381, GR202336002076. The certification dates are: November 22, 2023 and 2023, respectively Valid on December 8
No Data